Mellitus is developing a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk and as a clinical trial test for pharmaceutical development. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM).

Medical Devices

Mellitus

Mellitus' headquarters in Boston, MA, United States

Rick Saul

Kathy Welch

Thomas J. Musci

Ellie McGuire

The Board Members at Mellitus provide strategic oversight, governance, and guidance to ensure the successful development and commercialization of the company's novel diagnostic tests. They bring diverse expertise to shape the company’s vision, support executive decisions, and oversee financial and operational health, with a particular emphasis on the lead product candidate for Gestational Diabetes Mellitus (GDM).

Board Members

The Leadership Team at Mellitus is responsible for setting the strategic direction of the company and overseeing the development of its innovative in vitro diagnostic test for Glycated CD59. Comprising co-founders with a wealth of expertise, the team makes key decisions regarding product development, corporate partnerships, and navigating regulatory pathways, all aimed at advancing the company's mission to improve diabetes screening and management.

Mellitus

Org chart

Board & advisors

Teams

Board Members

Leadership Team

Offices

Mellitus

Org chart

Board & advisors

Teams

Board Members

Leadership Team

Offices

Related companies